Skip to main content
رجوع
Watch Compare

Galmed Pharmaceuticals Ltd.

جودة البيانات: 83%
GLMD
Nasdaq Manufacturing Chemicals
KWD 0.79
▲ KWD 0.16 (26.14%)
القيمة السوقية: 5.18 M
السعر
KWD 0.79
القيمة السوقية
5.18 M
نطاق اليوم
KWD 0.76 — KWD 1.26
نطاق 52 أسبوعًا
KWD 0.41 — KWD 2.68
حجم التداول
175,915,924
فتح KWD 1.16
متوسط 50 يوم / 200 يوم
KWD 0.62
25.79% above
متوسط 50 يوم / 200 يوم
KWD 1.17
33.09% below

Quick Summary

النقاط الرئيسية

Negative free cash flow of -6.32 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-52.02%
أعلى من متوسط القطاع (-53.41%)
ROICN/A
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio7.98
Interest CoverageN/A

التقييم

PE (TTM)
-0.50
أعلى من متوسط القطاع (-1.48)
P/B Ratio0.27
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -0.5 -1.5
P/B 0.3 1.6
ROE % -52.0 -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock

DLHAX DLHAX
0.00% weight
DLRHX DLRHX
0.00% weight
DLHIX DLHIX
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -10.31 M
ROE -52.02% ROA -46.30%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -6.32 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 7.98
Interest Coverage N/A Asset Turnover N/A
Working Capital 17.25 M Tangible Book Value 19.11 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.50 Forward P/E N/A
P/B Ratio 0.27 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -121.86%
Market Cap 5.18 M Enterprise Value 1.87 M
Per Share
EPS (Diluted TTM) 2.39 Revenue / Share N/A
FCF / Share -0.96 OCF / Share -0.96
EPS CAGR (1Y) -70.42% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 61.26%
SBC-Adj. FCF -7.38 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -10.31 M -7.52 M -6.91 M -17.87 M -32.47 M
EPS (Diluted) 2.39 8.08 2.50 — —
Gross Profit — — — — —
Operating Income — — — — —
EBITDA — — — — —
R&D Expenses 4.87 M 2.98 M 3.57 M 13.00 M 27.22 M
SG&A Expenses — — — — —
D&A 83,000.0 83,000.0 31,000.0 35,000.0 42,000.0
Interest Expense — — — — —
Income Tax 0.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 18.63 M 18.50 M 16.63 M 16.56 M 36.61 M
Total Liabilities — — — — —
Shareholders' Equity 15.78 M 16.33 M 13.88 M 13.42 M 30.50 M
Total Debt — — — — —
Cash & Equivalents 3.99 M 4.65 M 2.86 M 2.02 M 2.88 M
Current Assets 18.63 M 16.12 M 13.24 M 14.72 M 36.05 M
Current Liabilities 2.85 M 2.17 M 2.75 M 3.09 M 5.88 M